Breast Cancer Cell-Derived Adenosine Enhances Generation and Suppressor Function of Human Adaptive Regulatory T Cells.

Szczegóły
Abstrakt

Tytuł:: Breast Cancer Cell-Derived Adenosine Enhances Generation and Suppressor Function of Human Adaptive Regulatory T Cells.
Autorzy:: Mandapathil M; Department of Otorhinolaryngology, Asklepios Clinic St. Georg, 20099 Hamburg, Germany.; Department of Otorhinolaryngol Head & Neck Surg, Philipps University of Marburg, 35033 Marburg, Germany.
Szczepanski MJ; Department of Biochemistry, Medical University of Warsaw, PL-02097 Warsaw, Poland.
Jackson EK; Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Lang S; Department of Otorhinolaryngology, University of Duisburg-Essen, 45147 Essen, Germany.
Whiteside TL; UPMC Hillman Cancer Center, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Źródło:: Journal of personalized medicine [J Pers Med] 2021 Jul 30; Vol. 11 (8). Date of Electronic Publication: 2021 Jul 30.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI AG, 2011-
References:: Int J Oncol. 2008 Mar;32(3):527-35. (PMID: 18292929)
J Exp Med. 2007 Jun 11;204(6):1257-65. (PMID: 17502665)
Am J Pathol. 2007 Oct;171(4):1395-404. (PMID: 17823293)
Clin Cancer Res. 2010 Dec 15;16(24):6100-10. (PMID: 21169259)
Biomed Res Int. 2014;2014:460654. (PMID: 25126561)
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629. (PMID: 32514148)
J Cell Physiol. 2019 Jan 28;:. (PMID: 30693504)
Clin Cancer Res. 2008 Oct 1;14(19):5947-52. (PMID: 18829471)
J Mol Med (Berl). 2010 Jun;88(6):577-88. (PMID: 20225066)
Arch Pathol Lab Med. 2010 Jan;134(1):130-3. (PMID: 20073617)
J Cell Physiol. 2018 Mar;233(3):2032-2057. (PMID: 28233320)
Cancer Immunol Immunother. 2007 Sep;56(9):1429-42. (PMID: 17265021)
Virchows Arch. 2020 Apr;476(4):569-576. (PMID: 31853625)
Blood. 2007 Aug 15;110(4):1225-32. (PMID: 17449799)
Immunity. 2007 Oct;27(4):635-46. (PMID: 17919943)
Asia Pac J Clin Oncol. 2020 Sep 9;:. (PMID: 32905661)
Curr Opin Pharmacol. 2016 Aug;29:7-16. (PMID: 27209048)
Immunity. 2018 Dec 18;49(6):1004-1019. (PMID: 30566879)
Cancer Immunol Immunother. 2011 Jan;60(1):111-22. (PMID: 20960188)
J Immunother Cancer. 2018 Jun 18;6(1):57. (PMID: 29914571)
J Biol Chem. 2009 Nov 27;284(48):33097-106. (PMID: 19801686)
Semin Cancer Biol. 2012 Aug;22(4):327-34. (PMID: 22465232)
J Biol Chem. 2010 Mar 5;285(10):7176-86. (PMID: 19858205)
Curr Med Chem. 2018;25(19):2260-2271. (PMID: 29345574)
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83. (PMID: 20061007)
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7. (PMID: 16916931)
Oncoimmunology. 2019 Apr 2;8(6):e1593809. (PMID: 31069159)
Br J Pharmacol. 2008 Mar;153 Suppl 1:S457-64. (PMID: 18311159)
Cancer Res. 2007 Sep 15;67(18):8865-73. (PMID: 17875728)
J Transl Med. 2007 May 04;5:23. (PMID: 17480228)
Ann Oncol. 2018 Apr 1;29(4):1056-1062. (PMID: 29145561)
Expert Rev Anticancer Ther. 2017 Jun;17(6):527-535. (PMID: 28399672)
Int J Mol Sci. 2019 Nov 14;20(22):. (PMID: 31739402)
J Biol Chem. 2010 Sep 3;285(36):27571-80. (PMID: 20558731)
Blood. 2008 Jan 1;111(1):251-9. (PMID: 17909080)
Cancer Immunol Res. 2016 Apr;4(4):354-65. (PMID: 26880715)
Oncol Rep. 2002 Jan-Feb;9(1):113-7. (PMID: 11748467)
Grant Information:: P30 DK079307 United States DK NIDDK NIH HHS; U01 DE029759 United States DE NIDCR NIH HHS
Contributed Indexing:: Keywords: CD73; Treg; adenosine; breast cancer (BrCa); immunosuppression
Entry Date(s):: Date Created: 20210827 Latest Revision: 20220519
Update Code:: 20240104
PubMed Central ID:: PMC8401826
DOI:: 10.3390/jpm11080754
PMID:: 34442398
: Czasopismo naukowe

Full Text Finder

Introduction: Adaptive regulatory T cells (Tr1) are induced in the periphery by environmental stimuli. CD73 expression and adenosine (ADO) production by tumor cells may influence Tr1 generation and their immunosuppressive activity.
Material and Methods: Tr1 were generated in co-cultures of CD4+CD25neg T cells, autologous immature dendritic cells (iDC), and irradiated ADO-producing CD73+ or non-producing CD73neg breast cancer (BrCa) cell lines (TU). The expression of ectonucleotidases and other surface markers on Tr1 was determined by flow cytometry. Tr1-mediated suppression of proliferation was evaluated in CFSE-based assays. Luciferase-based ATP detection assays and mass spectrometry were used to measure ATP hydrolysis and ADO levels. Cytokine levels were measured by ELISA or Luminex. CD73 expression on tumor cells or T cells in TU tissues was assessed by immunofluorescence.
Results: CD73+ TU induced higher numbers of Tr1 cells ( p < 0.01) than CD73neg TU. Tr1TU73+ hydrolyzed more exogenous ATP, produced more ADO, and mediated higher suppression than Tr1TU73neg ( p < 0.05 for all). ARL67156, an ectonucleotidase inhibitor, and ZM241385, A2A receptor antagonist, reduced suppression of proliferation mediated by Tr1TU73+ cells ( p < 0.01). Basal-like primary BrCa cells expressed higher levels of ectonucleotidases and induced more Tr1 than less aggressive primary luminal-like BrCa.
Conclusion: BrCa producing ADO (CD73+ TU) favor the induction of Tr1, which expresses CD39 and CD73, hydrolyzes ATP to ADO, and effectively suppresses anti-tumor immunity.

Informacja